Related Experiment Video
Updated: Jul 3, 2026

Induction of Petite Colonies in Candida glabrate via Rose Bengal-Mediated Photodynamic Therapy
Published on: March 29, 2024
Routine use of fluconazole prophylaxis in a neonatal intensive care unit does not select natively
Paolo Manzoni1, Marialisa Leonessa, Paolo Galletto
1Neonatology and Hospital NICU, Azienda Ospedaliera Regina Margherita-S. Anna C. Spezia 60, 10136 Torino, Italy. paolomanzoni@hotmail.com
Insights
Routine fluconazole prophylaxis in very low birth weight (VLBW) infants did not increase rates of fluconazole-resistant Candida species. This antifungal strategy remains effective for preventing fungal colonization and infection in this vulnerable population.
Area of Science:
- Neonatal Medicine
- Infectious Diseases
- Pharmacology
Background:
- Fluconazole prophylaxis is standard for very low birth weight (VLBW) infants to prevent fungal infections.
- Prolonged use raises concerns about emerging antifungal resistance and fluconazole-resistant Candida species.
Purpose of the Study:
- To assess the impact of routine fluconazole prophylaxis on the incidence of fluconazole-resistant Candida species in VLBW infants.
- To compare the prevalence of resistant Candida species before and after the implementation of prophylaxis.
Main Methods:
- Retrospective analysis of clinical and surveillance fungal isolates from VLBW infants over a 10-year period (1997-2006).
- Fungal isolates were speciated, and incidence rates of colonization and infection by natively fluconazole-resistant (NFR) Candida species were calculated.
- Comparison between a 6-year prophylaxis period (2001-2006) and a 4-year preprophylaxis period (1997-2000).
Main Results:
- Colonization by NFR-Candida species ranged from 2.8% to 6.6% annually, with no increasing trend observed.
- 18 of 434 (4.1%) VLBW infants were colonized by NFR-Candida species.
- Five systemic infections (1.1% incidence) by NFR-Candida species occurred, with no significant difference compared to the preprophylaxis period (3.7% colonization, 1.4% infection).
Conclusions:
- Routine fluconazole prophylaxis in VLBW neonates does not lead to the emergence of natively fluconazole-resistant Candida species.
- The antifungal prophylaxis strategy remains effective in preventing resistant fungal infections in this population.
Background:
We have previously demonstrated efficacy against fungal colonization and infection of fluconazole prophylaxis that was routinely administered since 2001 in our ICU for preterm infants <1500 g at birth (VLBW). With prolonged use, concerns exist for the emergence of acquired fungal resistance and of Candida subspecies that are natively fluconazole-resistant (NFR), mostly Candida glabrata and Candida krusei.
Methods:
We evaluated retrospectively all clinical and surveillance fungal isolates obtained from VLBW infants in our NICU during a 10-year period (1997-2006). Each fungal isolate was speciated, infants colonized or infected with NFR-Candida spp were identified and the incidence rates of colonization and infection by these fungal species were calculated. A comparison was made of the 6-year (2001-2006) prophylaxis period with the 4-year (1997-2000) preprophylaxis period.
Results:
Overall, colonization by NFR-Candida spp ranged between 2.8% and 6.6% of VLBW infants yearly admitted, without any increasing trend during the study period. There were 18 of 434 (4.1%) neonates colonized by these species. Five episodes of systemic fungal infections caused by NFR-Candida spp occurred (incidence rate, 1.1%). No significant differences were detected when compared with the preprophylaxis period, when 11 of 295 infants (3.7%) were colonized by NFR-Candida spp and 4 episodes of infection occurred (1.4%) (P = 0.84 and 0.76, respectively).
Conclusions:
Fluconazole prophylaxis administered to VLBW neonates in 4- to 6-week courses after birth does not lead to the emergence of natively fluconazole-resistant Candida spp.
Related Concept Videos
Cryptococcal Meningitis
Antifungal Agents
Candidiasis
Pharmacokinetics in Pediatric Patients: Drug Excretion

